Clinical Trials Directory

Trials / Completed

CompletedNCT03643809

Epidemiology of SAIDs.

Epidemiology and Clinico-genetic Correlations of Auto-inflammatory Diseases

Status
Completed
Phase
Study type
Observational
Enrollment
500 (actual)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Systemic autoinflammatory diseases (SAIDs) are inflammatory conditions caused by a defect of the innate immune system. Most are hereditary, but little is known on recent entities. The investigators aim to (1) establish correlations between the main mutations and symptoms presented by patients (genotype-phenotype correlation), and (2) describe the most recently described clinical, genetic, and demographic characteristics of SAIDs.

Detailed description

Background SAIDs are a heterogeneous group of diseases linked to a deregulation of the innate immune system. They are characterized by systemic or organ inflammatory attacks. In the absence of accurate diagnosis and adequate treatment, evolution can be lethal. Most SAIDs are hereditary, and the diagnosis is based on genetic analysis because the clinical features overlap. The investigators have been among the first in France to routinely develop Next Generation Sequencing (NGS), which allows a simultaneous and exhaustive analysis of a constantly evolving panel of now more than 60 genes involved in SAIDs. While there are epidemiological studies on the first described MAIs, nothing has been done regarding the newest clinical entities. Objectives The investigators want to study and value the data the investigators have collected on the most recent SAIDs (500 patients) Main objective: Establish correlations between the main mutations and symptoms presented by patients (genotype-phenotype correlation). Secondary objectives: Descriptive epidemiology study: Describe the most recently described clinical, genetic, and demographic characteristics of SAIDs. Methodology The investigators have over the last 20 years set up a database that continues to evolve. These data are collected prospectively from patients (N\> 7000) with SAID refered to our laboratory for genetic analysis. This database contains invaluable demographic, clinical and genetic data, carefully collected for each patient, on a standard file of analysis request made with clinicians from the reference center for auto-inflammatory diseases and amyloidosis (CeRéMAIA). The collection of consent is systematic (declared collection).

Conditions

Timeline

Start date
2018-07-07
Primary completion
2019-01-30
Completion
2020-01-30
First posted
2018-08-23
Last updated
2020-03-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03643809. Inclusion in this directory is not an endorsement.